InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.62
(
-0.09%
)
Bitcoin
61,180.00
(
0.00%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rkrw

Send PM Follow Ignore
Followers 45
Posts 3204
Boards Moderated 0
Alias Born 12/29/2003

rkrw

Member Level

Re: DewDiligence post# 76385

Wednesday, 04/22/2009 8:08:57 AM

Wednesday, April 22, 2009 8:08:57 AM

Post# of 252939
If that's the case, obviously rdea can't license 806 prior to phase 2B without some sort of amended agreement with Valeant. Valeant has no rights to the gout program.

<<For the HIV program (as opposed to the gout program), this option may be moot insofar as RDEA does not plan to start a phase-2b trial without a partner.>>>
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up